APO Research
Talk to an analyst

APO RESEARCH · REPORT

Androgen Receptor (AR) Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Androgen Receptor (AR) Antagonist Market Outlook and Growth Opportunities 2026

27 December 2025194 pages

Choose your research edition.

Industry ResearchAndrogen Receptor (AR) Antagonist Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Androgen Receptor (AR) Antagonist Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Androgen Receptor (AR) Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Androgen Receptor (AR) Antagonist Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Androgen Receptor (AR) Antagonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Androgen Receptor (AR) Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Androgen Receptor (AR) Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Androgen Receptor (AR) Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Androgen Receptor (AR) Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Androgen Receptor (AR) Antagonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Androgen Receptor (AR) Antagonist market include Kaituo Pharmaceutical, Pfizer, Hengrui Medicine, Bayer, R&D Systems, Janssen Pharmaceuticals and Astellas Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Androgen Receptor (AR) Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Androgen Receptor (AR) Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Androgen Receptor (AR) Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Androgen Receptor (AR) Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Androgen Receptor (AR) Antagonist Segment by Company

Kaituo Pharmaceutical

Pfizer

Hengrui Medicine

Bayer

R&D Systems

Janssen Pharmaceuticals

Astellas Pharma

Androgen Receptor (AR) Antagonist Segment by Type

Steroidal AR Antagonists

Nonsteroidal AR Antagonists

Androgen Receptor (AR) Antagonist Segment by Application

Prostate Cancer

Breast Cancer

Others

Androgen Receptor (AR) Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Androgen Receptor (AR) Antagonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Androgen Receptor (AR) Antagonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Androgen Receptor (AR) Antagonist significant trends, drivers, influence factors in global and regions.

6. To analyze Androgen Receptor (AR) Antagonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Androgen Receptor (AR) Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Androgen Receptor (AR) Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Androgen Receptor (AR) Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Androgen Receptor (AR) Antagonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Androgen Receptor (AR) Antagonist industry.

Chapter 3: Detailed analysis of Androgen Receptor (AR) Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Androgen Receptor (AR) Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Androgen Receptor (AR) Antagonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Androgen Receptor (AR) Antagonist Industry Trends Table 2. Androgen Receptor (AR) Antagonist Industry Drivers Table 3. Androgen Receptor (AR) Antagonist Industry Opportunities and Challenges Table 4. Androgen Receptor (AR) Antagonist Industry Restraints Table 5. Global Androgen Receptor (AR) Antagonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Androgen Receptor (AR) Antagonist Revenue Share by Company (2021-2026) Table 7. Global Androgen Receptor (AR) Antagonist Sales Volume by Company (K Tons) & (2021-2026) Table 8. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Company (2021-2026) Table 9. Global Androgen Receptor (AR) Antagonist Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Androgen Receptor (AR) Antagonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global Androgen Receptor (AR) Antagonist Key Company Manufacturing Base & Headquarters Table 12. Global Androgen Receptor (AR) Antagonist Company, Product Type & Application Table 13. Global Androgen Receptor (AR) Antagonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Androgen Receptor (AR) Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Steroidal AR Antagonists Table 18. Significant Companies of Nonsteroidal AR Antagonists Table 19. Global Androgen Receptor (AR) Antagonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Tons) Table 20. Global Androgen Receptor (AR) Antagonist Sales Volume by Type (2021-2026) & (K Tons) Table 21. Global Androgen Receptor (AR) Antagonist Sales Volume by Type (2027-2032) & (K Tons) Table 22. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Type (2021-2026) Table 23. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Type (2027-2032) Table 24. Global Androgen Receptor (AR) Antagonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Androgen Receptor (AR) Antagonist Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Androgen Receptor (AR) Antagonist Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Androgen Receptor (AR) Antagonist Sales Value Share by Type (2021-2026) Table 28. Global Androgen Receptor (AR) Antagonist Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Prostate Cancer Table 30. Significant Companies of Breast Cancer Table 31. Significant Companies of Others Table 32. Global Androgen Receptor (AR) Antagonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Tons) Table 33. Global Androgen Receptor (AR) Antagonist Sales Volume by Application (2021-2026) & (K Tons) Table 34. Global Androgen Receptor (AR) Antagonist Sales Volume by Application (2027-2032) & (K Tons) Table 35. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Application (2021-2026) Table 36. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Application (2027-2032) Table 37. Global Androgen Receptor (AR) Antagonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Androgen Receptor (AR) Antagonist Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Androgen Receptor (AR) Antagonist Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Androgen Receptor (AR) Antagonist Sales Value Share by Application (2021-2026) Table 41. Global Androgen Receptor (AR) Antagonist Sales Value Share by Application (2027-2032) Table 42. Global Androgen Receptor (AR) Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 43. Global Androgen Receptor (AR) Antagonist Sales by Region (2021-2026) & (K Tons) Table 44. Global Androgen Receptor (AR) Antagonist Sales Market Share by Region (2021-2026) Table 45. Global Androgen Receptor (AR) Antagonist Sales by Region (2027-2032) & (K Tons) Table 46. Global Androgen Receptor (AR) Antagonist Sales Market Share by Region (2027-2032) Table 47. Global Androgen Receptor (AR) Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Androgen Receptor (AR) Antagonist Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Androgen Receptor (AR) Antagonist Sales Value Share by Region (2021-2026) Table 50. Global Androgen Receptor (AR) Antagonist Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Androgen Receptor (AR) Antagonist Sales Value Share by Region (2027-2032) Table 52. Global Androgen Receptor (AR) Antagonist Market Average Price (US$/Ton) by Region (2021-2026) Table 53. Global Androgen Receptor (AR) Antagonist Market Average Price (US$/Ton) by Region (2027-2032) Table 54. Global Androgen Receptor (AR) Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Table 55. Global Androgen Receptor (AR) Antagonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Androgen Receptor (AR) Antagonist Sales by Country (2021-2026) & (K Tons) Table 57. Global Androgen Receptor (AR) Antagonist Sales Market Share by Country (2021-2026) Table 58. Global Androgen Receptor (AR) Antagonist Sales by Country (2027-2032) & (K Tons) Table 59. Global Androgen Receptor (AR) Antagonist Sales Market Share by Country (2027-2032) Table 60. Global Androgen Receptor (AR) Antagonist Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Androgen Receptor (AR) Antagonist Sales Value Market Share by Country (2021-2026) Table 62. Global Androgen Receptor (AR) Antagonist Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Androgen Receptor (AR) Antagonist Sales Value Market Share by Country (2027-2032) Table 64. Kaituo Pharmaceutical Company Information Table 65. Kaituo Pharmaceutical Business Overview Table 66. Kaituo Pharmaceutical Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Kaituo Pharmaceutical Androgen Receptor (AR) Antagonist Product Portfolio Table 68. Kaituo Pharmaceutical Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. Pfizer Androgen Receptor (AR) Antagonist Product Portfolio Table 73. Pfizer Recent Development Table 74. Hengrui Medicine Company Information Table 75. Hengrui Medicine Business Overview Table 76. Hengrui Medicine Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Hengrui Medicine Androgen Receptor (AR) Antagonist Product Portfolio Table 78. Hengrui Medicine Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Bayer Androgen Receptor (AR) Antagonist Product Portfolio Table 83. Bayer Recent Development Table 84. R&D Systems Company Information Table 85. R&D Systems Business Overview Table 86. R&D Systems Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. R&D Systems Androgen Receptor (AR) Antagonist Product Portfolio Table 88. R&D Systems Recent Development Table 89. Janssen Pharmaceuticals Company Information Table 90. Janssen Pharmaceuticals Business Overview Table 91. Janssen Pharmaceuticals Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Janssen Pharmaceuticals Androgen Receptor (AR) Antagonist Product Portfolio Table 93. Janssen Pharmaceuticals Recent Development Table 94. Astellas Pharma Company Information Table 95. Astellas Pharma Business Overview Table 96. Astellas Pharma Androgen Receptor (AR) Antagonist Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Astellas Pharma Androgen Receptor (AR) Antagonist Product Portfolio Table 98. Astellas Pharma Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Androgen Receptor (AR) Antagonist Distributors List Table 102. Androgen Receptor (AR) Antagonist Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Androgen Receptor (AR) Antagonist Product Image Figure 2. Global Androgen Receptor (AR) Antagonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Androgen Receptor (AR) Antagonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global Androgen Receptor (AR) Antagonist Sales (2021-2032) & (K Tons) Figure 5. Global Androgen Receptor (AR) Antagonist Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Androgen Receptor (AR) Antagonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Steroidal AR Antagonists Image Figure 10. Nonsteroidal AR Antagonists Image Figure 11. Global Androgen Receptor (AR) Antagonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 12. Global Androgen Receptor (AR) Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Type (2021-2032) Figure 14. Global Androgen Receptor (AR) Antagonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Androgen Receptor (AR) Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Androgen Receptor (AR) Antagonist Sales Value Share by Type (2021-2032) Figure 17. Prostate Cancer Image Figure 18. Breast Cancer Image Figure 19. Others Image Figure 20. Global Androgen Receptor (AR) Antagonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 21. Global Androgen Receptor (AR) Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Androgen Receptor (AR) Antagonist Sales Volume Share by Application (2021-2032) Figure 23. Global Androgen Receptor (AR) Antagonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Androgen Receptor (AR) Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Androgen Receptor (AR) Antagonist Sales Value Share by Application (2021-2032) Figure 26. Global Androgen Receptor (AR) Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Figure 27. Global Androgen Receptor (AR) Antagonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Androgen Receptor (AR) Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Androgen Receptor (AR) Antagonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Androgen Receptor (AR) Antagonist Sales Value (2021-2032) & (US$ Million) Figure 31. North America Androgen Receptor (AR) Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Androgen Receptor (AR) Antagonist Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Androgen Receptor (AR) Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Androgen Receptor (AR) Antagonist Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Androgen Receptor (AR) Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Androgen Receptor (AR) Antagonist Sales Value (2021-2032) & (US$ Million) Figure 37. South America Androgen Receptor (AR) Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Androgen Receptor (AR) Antagonist Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Androgen Receptor (AR) Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Androgen Receptor (AR) Antagonist Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Androgen Receptor (AR) Antagonist Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Steroidal AR Antagonists
  • Nonsteroidal AR Antagonists
Applications
  • Prostate Cancer
  • Breast Cancer
  • Others
Companies covered
  • Kaituo Pharmaceutical
  • Pfizer
  • Hengrui Medicine
  • Bayer
  • R&D Systems
  • Janssen Pharmaceuticals
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Androgen Receptor (AR) Antagonist Sales Value (2021-2032)
  4. 1.2.2 Global Androgen Receptor (AR) Antagonist Sales Volume (2021-2032)
  5. 1.2.3 Global Androgen Receptor (AR) Antagonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Androgen Receptor (AR) Antagonist Market Dynamics
  1. 2.1 Androgen Receptor (AR) Antagonist Industry Trends
  2. 2.2 Androgen Receptor (AR) Antagonist Industry Drivers
  3. 2.3 Androgen Receptor (AR) Antagonist Industry Opportunities and Challenges
  4. 2.4 Androgen Receptor (AR) Antagonist Industry Restraints
3 Androgen Receptor (AR) Antagonist Market by Company
  1. 3.1 Global Androgen Receptor (AR) Antagonist Company Revenue Ranking in 2025
  2. 3.2 Global Androgen Receptor (AR) Antagonist Revenue by Company (2021-2026)
  3. 3.3 Global Androgen Receptor (AR) Antagonist Sales Volume by Company (2021-2026)
  4. 3.4 Global Androgen Receptor (AR) Antagonist Average Price by Company (2021-2026)
  5. 3.5 Global Androgen Receptor (AR) Antagonist Company Ranking (2024-2026)
  6. 3.6 Global Androgen Receptor (AR) Antagonist Company Manufacturing Base and Headquarters
  7. 3.7 Global Androgen Receptor (AR) Antagonist Company Product Type and Application
  8. 3.8 Global Androgen Receptor (AR) Antagonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Androgen Receptor (AR) Antagonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Androgen Receptor (AR) Antagonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Androgen Receptor (AR) Antagonist Market by Type
  1. 4.1 Androgen Receptor (AR) Antagonist Type Introduction
  2. 4.1.1 Steroidal AR Antagonists
  3. 4.1.2 Nonsteroidal AR Antagonists
  4. 4.2 Global Androgen Receptor (AR) Antagonist Sales Volume by Type
  5. 4.2.1 Global Androgen Receptor (AR) Antagonist Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Androgen Receptor (AR) Antagonist Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Androgen Receptor (AR) Antagonist Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Androgen Receptor (AR) Antagonist Sales Value by Type
  9. 4.3.1 Global Androgen Receptor (AR) Antagonist Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Androgen Receptor (AR) Antagonist Sales Value by Type (2021-2032)
  11. 4.3.3 Global Androgen Receptor (AR) Antagonist Sales Value Share by Type (2021-2032)
5 Androgen Receptor (AR) Antagonist Market by Application
  1. 5.1 Androgen Receptor (AR) Antagonist Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Others
  5. 5.2 Global Androgen Receptor (AR) Antagonist Sales Volume by Application
  6. 5.2.1 Global Androgen Receptor (AR) Antagonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Androgen Receptor (AR) Antagonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Androgen Receptor (AR) Antagonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Androgen Receptor (AR) Antagonist Sales Value by Application
  10. 5.3.1 Global Androgen Receptor (AR) Antagonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Androgen Receptor (AR) Antagonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global Androgen Receptor (AR) Antagonist Sales Value Share by Application (2021-2032)
6 Androgen Receptor (AR) Antagonist Regional Sales and Value Analysis
  1. 6.1 Global Androgen Receptor (AR) Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Androgen Receptor (AR) Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global Androgen Receptor (AR) Antagonist Sales by Region: 2021-2026
  4. 6.2.2 Global Androgen Receptor (AR) Antagonist Sales by Region (2027-2032)
  5. 6.3 Global Androgen Receptor (AR) Antagonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Androgen Receptor (AR) Antagonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global Androgen Receptor (AR) Antagonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global Androgen Receptor (AR) Antagonist Sales Value by Region (2027-2032)
  9. 6.5 Global Androgen Receptor (AR) Antagonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Androgen Receptor (AR) Antagonist Sales Value (2021-2032)
  12. 6.6.2 North America Androgen Receptor (AR) Antagonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Androgen Receptor (AR) Antagonist Sales Value (2021-2032)
  15. 6.7.2 Europe Androgen Receptor (AR) Antagonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Androgen Receptor (AR) Antagonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Androgen Receptor (AR) Antagonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Androgen Receptor (AR) Antagonist Sales Value (2021-2032)
  21. 6.9.2 South America Androgen Receptor (AR) Antagonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Androgen Receptor (AR) Antagonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Androgen Receptor (AR) Antagonist Sales Value Share by Country, 2025 VS 2032
7 Androgen Receptor (AR) Antagonist Country-level Sales and Value Analysis
  1. 7.1 Global Androgen Receptor (AR) Antagonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Androgen Receptor (AR) Antagonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Androgen Receptor (AR) Antagonist Sales by Country (2021-2032)
  4. 7.3.1 Global Androgen Receptor (AR) Antagonist Sales by Country (2021-2026)
  5. 7.3.2 Global Androgen Receptor (AR) Antagonist Sales by Country (2027-2032)
  6. 7.4 Global Androgen Receptor (AR) Antagonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global Androgen Receptor (AR) Antagonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global Androgen Receptor (AR) Antagonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Androgen Receptor (AR) Antagonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Androgen Receptor (AR) Antagonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Androgen Receptor (AR) Antagonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Kaituo Pharmaceutical
  2. 8.1.1 Kaituo Pharmaceutical Company Information
  3. 8.1.2 Kaituo Pharmaceutical Business Overview
  4. 8.1.3 Kaituo Pharmaceutical Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Kaituo Pharmaceutical Androgen Receptor (AR) Antagonist Product Portfolio
  6. 8.1.5 Kaituo Pharmaceutical Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Androgen Receptor (AR) Antagonist Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Hengrui Medicine
  14. 8.3.1 Hengrui Medicine Company Information
  15. 8.3.2 Hengrui Medicine Business Overview
  16. 8.3.3 Hengrui Medicine Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Hengrui Medicine Androgen Receptor (AR) Antagonist Product Portfolio
  18. 8.3.5 Hengrui Medicine Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Androgen Receptor (AR) Antagonist Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 R&D Systems
  26. 8.5.1 R&D Systems Company Information
  27. 8.5.2 R&D Systems Business Overview
  28. 8.5.3 R&D Systems Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 R&D Systems Androgen Receptor (AR) Antagonist Product Portfolio
  30. 8.5.5 R&D Systems Recent Developments
  31. 8.6 Janssen Pharmaceuticals
  32. 8.6.1 Janssen Pharmaceuticals Company Information
  33. 8.6.2 Janssen Pharmaceuticals Business Overview
  34. 8.6.3 Janssen Pharmaceuticals Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Janssen Pharmaceuticals Androgen Receptor (AR) Antagonist Product Portfolio
  36. 8.6.5 Janssen Pharmaceuticals Recent Developments
  37. 8.7 Astellas Pharma
  38. 8.7.1 Astellas Pharma Company Information
  39. 8.7.2 Astellas Pharma Business Overview
  40. 8.7.3 Astellas Pharma Androgen Receptor (AR) Antagonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Astellas Pharma Androgen Receptor (AR) Antagonist Product Portfolio
  42. 8.7.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Androgen Receptor (AR) Antagonist Value Chain Analysis
  2. 9.1.1 Androgen Receptor (AR) Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Androgen Receptor (AR) Antagonist Sales Mode & Process
  6. 9.2 Androgen Receptor (AR) Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Androgen Receptor (AR) Antagonist Distributors
  9. 9.2.3 Androgen Receptor (AR) Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst